Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ4B2E
|
|||
| Drug Name |
SY-2101
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Acute promyelocytic leukaemia [ICD-11: 2A60.0; ICD-10: C92.9; ICD-9: 205] | Phase 1 | [1] | |
| Company |
Syros Pharmaceuticals Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | F-box-like/WD repeat-containing protein TBL1X (TBL1X) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04996030) An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic Leukemia. U.S.National Institutes of Health. | |||
| REF 2 | Transducin beta-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica. 2021 Nov 1;106(11):2927-2939. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.